Pilot study comparing serum chemotherapy levels after intra-arterial and intravenous administration in dogs with naturally occurring urinary tract tumors

Meghan Kirsch, Chick Weisse, Allyson Berent, Craig Clifford, Nicole Leibman, Luke Anthony Wittenburg, Stephen B. Solomon, Kenneth Lamb

Research output: Contribution to journalArticle

Abstract

The proposed advantages of intra-arterial chemotherapy (IAC) are based on the premises of local dose escalation to the tumor and reduced availability of systemic drugs. There is a lack of objective pharmacokinetic data to confirm the advantage of IAC in dogs with naturally occurring urogenital tumors. The objective of this study was to determine if IAC administration in urogenital tumors would result in decreased systemic drug exposure when compared to intravenous routes. Twenty-two dogs with naturally occurring urogenital tumors were enrolled in this prospective case-controlled study. Mitoxantrone, doxorubicin, or carboplatin were administered by IAC and intravenous routes [intravenous awake (intravenous chemotherapy — IVC) and under general anesthesia (IVGAC)] 3 weeks apart. Serum assays were used to determine the extent of systemic drug exposure. Dose-normalized peak systemic serum concentration (Cmax) and area under the serum drug concentration-time curve (AUC) were used to quantify systemic exposure. A total of 26 mitoxantrone treatments were administered to 10 dogs. While there was no significant difference in Cmax, the AUC was significantly lower after IAC compared with IVGAC. Ten doxorubicin treatments were administered to 5 dogs. There were no significant differences in Cmax or AUC. A total of 14 carboplatin treatments were administered to 7 dogs. The Cmax was significantly lower for IAC compared to IVC, while the AUC values were equivocal. This study demonstrates certain lower serum values may be achieved after IAC delivery of carboplatin and mitoxantrone. These chemotherapy agents may have a preferred pharmacological profile for regional chemotherapy delivery in dogs with urogenital tumors.

Original languageEnglish (US)
Pages (from-to)187-196
Number of pages10
JournalCanadian Journal of Veterinary Research
Volume83
Issue number3
StatePublished - Jul 1 2019

Fingerprint

urinary tract
Urinary Tract
intravenous injection
Intravenous Administration
drug therapy
Dogs
Drug Therapy
neoplasms
dogs
Serum
Neoplasms
Mitoxantrone
Area Under Curve
Carboplatin
drugs
doxorubicin
Pharmaceutical Preparations
Doxorubicin
dosage
General Anesthesia

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Pilot study comparing serum chemotherapy levels after intra-arterial and intravenous administration in dogs with naturally occurring urinary tract tumors. / Kirsch, Meghan; Weisse, Chick; Berent, Allyson; Clifford, Craig; Leibman, Nicole; Wittenburg, Luke Anthony; Solomon, Stephen B.; Lamb, Kenneth.

In: Canadian Journal of Veterinary Research, Vol. 83, No. 3, 01.07.2019, p. 187-196.

Research output: Contribution to journalArticle

Kirsch, Meghan ; Weisse, Chick ; Berent, Allyson ; Clifford, Craig ; Leibman, Nicole ; Wittenburg, Luke Anthony ; Solomon, Stephen B. ; Lamb, Kenneth. / Pilot study comparing serum chemotherapy levels after intra-arterial and intravenous administration in dogs with naturally occurring urinary tract tumors. In: Canadian Journal of Veterinary Research. 2019 ; Vol. 83, No. 3. pp. 187-196.
@article{554865be79d140f79d6b58b5933faf8d,
title = "Pilot study comparing serum chemotherapy levels after intra-arterial and intravenous administration in dogs with naturally occurring urinary tract tumors",
abstract = "The proposed advantages of intra-arterial chemotherapy (IAC) are based on the premises of local dose escalation to the tumor and reduced availability of systemic drugs. There is a lack of objective pharmacokinetic data to confirm the advantage of IAC in dogs with naturally occurring urogenital tumors. The objective of this study was to determine if IAC administration in urogenital tumors would result in decreased systemic drug exposure when compared to intravenous routes. Twenty-two dogs with naturally occurring urogenital tumors were enrolled in this prospective case-controlled study. Mitoxantrone, doxorubicin, or carboplatin were administered by IAC and intravenous routes [intravenous awake (intravenous chemotherapy — IVC) and under general anesthesia (IVGAC)] 3 weeks apart. Serum assays were used to determine the extent of systemic drug exposure. Dose-normalized peak systemic serum concentration (Cmax) and area under the serum drug concentration-time curve (AUC) were used to quantify systemic exposure. A total of 26 mitoxantrone treatments were administered to 10 dogs. While there was no significant difference in Cmax, the AUC was significantly lower after IAC compared with IVGAC. Ten doxorubicin treatments were administered to 5 dogs. There were no significant differences in Cmax or AUC. A total of 14 carboplatin treatments were administered to 7 dogs. The Cmax was significantly lower for IAC compared to IVC, while the AUC values were equivocal. This study demonstrates certain lower serum values may be achieved after IAC delivery of carboplatin and mitoxantrone. These chemotherapy agents may have a preferred pharmacological profile for regional chemotherapy delivery in dogs with urogenital tumors.",
author = "Meghan Kirsch and Chick Weisse and Allyson Berent and Craig Clifford and Nicole Leibman and Wittenburg, {Luke Anthony} and Solomon, {Stephen B.} and Kenneth Lamb",
year = "2019",
month = "7",
day = "1",
language = "English (US)",
volume = "83",
pages = "187--196",
journal = "Canadian Journal of Veterinary Research",
issn = "0830-9000",
publisher = "Canadian Veterinary Medical Association",
number = "3",

}

TY - JOUR

T1 - Pilot study comparing serum chemotherapy levels after intra-arterial and intravenous administration in dogs with naturally occurring urinary tract tumors

AU - Kirsch, Meghan

AU - Weisse, Chick

AU - Berent, Allyson

AU - Clifford, Craig

AU - Leibman, Nicole

AU - Wittenburg, Luke Anthony

AU - Solomon, Stephen B.

AU - Lamb, Kenneth

PY - 2019/7/1

Y1 - 2019/7/1

N2 - The proposed advantages of intra-arterial chemotherapy (IAC) are based on the premises of local dose escalation to the tumor and reduced availability of systemic drugs. There is a lack of objective pharmacokinetic data to confirm the advantage of IAC in dogs with naturally occurring urogenital tumors. The objective of this study was to determine if IAC administration in urogenital tumors would result in decreased systemic drug exposure when compared to intravenous routes. Twenty-two dogs with naturally occurring urogenital tumors were enrolled in this prospective case-controlled study. Mitoxantrone, doxorubicin, or carboplatin were administered by IAC and intravenous routes [intravenous awake (intravenous chemotherapy — IVC) and under general anesthesia (IVGAC)] 3 weeks apart. Serum assays were used to determine the extent of systemic drug exposure. Dose-normalized peak systemic serum concentration (Cmax) and area under the serum drug concentration-time curve (AUC) were used to quantify systemic exposure. A total of 26 mitoxantrone treatments were administered to 10 dogs. While there was no significant difference in Cmax, the AUC was significantly lower after IAC compared with IVGAC. Ten doxorubicin treatments were administered to 5 dogs. There were no significant differences in Cmax or AUC. A total of 14 carboplatin treatments were administered to 7 dogs. The Cmax was significantly lower for IAC compared to IVC, while the AUC values were equivocal. This study demonstrates certain lower serum values may be achieved after IAC delivery of carboplatin and mitoxantrone. These chemotherapy agents may have a preferred pharmacological profile for regional chemotherapy delivery in dogs with urogenital tumors.

AB - The proposed advantages of intra-arterial chemotherapy (IAC) are based on the premises of local dose escalation to the tumor and reduced availability of systemic drugs. There is a lack of objective pharmacokinetic data to confirm the advantage of IAC in dogs with naturally occurring urogenital tumors. The objective of this study was to determine if IAC administration in urogenital tumors would result in decreased systemic drug exposure when compared to intravenous routes. Twenty-two dogs with naturally occurring urogenital tumors were enrolled in this prospective case-controlled study. Mitoxantrone, doxorubicin, or carboplatin were administered by IAC and intravenous routes [intravenous awake (intravenous chemotherapy — IVC) and under general anesthesia (IVGAC)] 3 weeks apart. Serum assays were used to determine the extent of systemic drug exposure. Dose-normalized peak systemic serum concentration (Cmax) and area under the serum drug concentration-time curve (AUC) were used to quantify systemic exposure. A total of 26 mitoxantrone treatments were administered to 10 dogs. While there was no significant difference in Cmax, the AUC was significantly lower after IAC compared with IVGAC. Ten doxorubicin treatments were administered to 5 dogs. There were no significant differences in Cmax or AUC. A total of 14 carboplatin treatments were administered to 7 dogs. The Cmax was significantly lower for IAC compared to IVC, while the AUC values were equivocal. This study demonstrates certain lower serum values may be achieved after IAC delivery of carboplatin and mitoxantrone. These chemotherapy agents may have a preferred pharmacological profile for regional chemotherapy delivery in dogs with urogenital tumors.

UR - http://www.scopus.com/inward/record.url?scp=85069917430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069917430&partnerID=8YFLogxK

M3 - Article

C2 - 31308591

AN - SCOPUS:85069917430

VL - 83

SP - 187

EP - 196

JO - Canadian Journal of Veterinary Research

JF - Canadian Journal of Veterinary Research

SN - 0830-9000

IS - 3

ER -